After RBC Capital and Cantor Fitzgerald gave Pfizer (NYSE: PFE) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Vamil Divan maintained a Buy rating on Pfizer today and set a price target of $42.00. The company’s shares closed last Monday at $29.75, close to its 52-week low of $27.88.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -4.2% and a 39.5% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and Karuna Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $44.55 average price target, a 51.0% upside from current levels. In a report issued on March 12, RBC Capital also maintained a Buy rating on the stock with a $46.00 price target.
See today’s analyst top recommended stocks >>
Pfizer’s market cap is currently $165B and has a P/E ratio of 10.30. The company has a Price to Book ratio of -5.33.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PFE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
